- TRADE NAME: Ofev (Boehringer Ingelheim)
- INDICATIONS: Idiopathic pulmonary fibrosis
- CLASS: Angiogenesis inhibitor / antiangiogenic agent, Tyrosine kinase inhibitor
- HALF-LIFE: 9.5 hours
- FDA APPROVAL DATE: 10/15/2014
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Anticoagulants, Carbamazepine, Erythromycin, Phenytoin, St John's Wort
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the two DRUG REVIEW ARTICLE links (above) to see reviews of nintedanib in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 04/10/2025
